Cardinal Health (CAH)
(Delayed Data from NYSE)
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on continued partnership growth and a strong focus on strategic execution.
Abbott (ABT) to Expand Vascular Device Line With New Buyout
by Zacks Equity Research
Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges
by Zacks Equity Research
At Abbott (ABT), Medical Device sales growth is led by strong performance in Electrophysiology, Structural Heart and Diabetes Care.
BD's (BDX) Latest Combination Test Receives the FDA's EUA
by Zacks Equity Research
BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.
Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss
by Zacks Equity Research
With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.
DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Baxter (BAX) Q4 Earnings Miss Estimates, FY23 Outlook Weak
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect impact of additional sales from the legacy Hilrom's business acquired in 2021. Ongoing macroeconomic challenges hurt earnings significantly.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
Haemonetics (HAE) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
In the fiscal third quarter, Haemonetics (HAE) incurs higher research and development costs, primarily due to increased investments in product innovation.
CVS Health (CVS) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
CVS Health's (CVS) Retail/LTC segment revenues rise on increased prescription and front store volume, pharmacy drug mix and brand inflation.
Inspire Medical (INSP) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the fourth quarter.
This Portfolio of 3 Dividend Aristocrats Pays Monthly
by Derek Lewis
By targeting companies that pay out dividends in different months, investors can construct a portfolio that allows them to reap monthly income. Who doesn't love payday?
Here is Why Growth Investors Should Buy Cardinal (CAH) Now
by Zacks Equity Research
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
Catalent (CTLT) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Catalent (CTLT) records lower revenues in both segments in its second-quarter fiscal 2023, resulting in overall soft performance.
Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
LabCorp's (LH) New Launches, Planned Spinoff to Aid Growth
by Zacks Equity Research
In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.
Avantor (AVTR) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Despite Avantor's (AVTR) robust core organic sales across its segments, it reports an overall soft Q4 performance.
Cardinal Health, Inc. (CAH) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Cardinal (CAH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks Industry Outlook Highlights McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical
by Zacks Equity Research
McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical have been highlighted in this Industry Outlook article.
Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cardinal Health (CAH) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Company News for Feb 3, 2023
by Zacks Equity Research
Companies in The news Are: META, BMY, PH, CAH.
5 Dental Supplies Stocks to Buy Amid Recovering Prospects
by Indrajit Bandyopadhyay
Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.